174 related articles for article (PubMed ID: 27480941)
1. Crystal structures of APOBEC3G N-domain alone and its complex with DNA.
Xiao X; Li SX; Yang H; Chen XS
Nat Commun; 2016 Aug; 7():12193. PubMed ID: 27480941
[TBL] [Abstract][Full Text] [Related]
2. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G.
Morse M; Huo R; Feng Y; Rouzina I; Chelico L; Williams MC
Nat Commun; 2017 Sep; 8(1):597. PubMed ID: 28928403
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of DNA cytidine deaminase ABOBEC3G catalytic deamination domain suggests a binding mode of full-length enzyme to single-stranded DNA.
Lu X; Zhang T; Xu Z; Liu S; Zhao B; Lan W; Wang C; Ding J; Cao C
J Biol Chem; 2015 Feb; 290(7):4010-21. PubMed ID: 25542899
[TBL] [Abstract][Full Text] [Related]
4. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
[TBL] [Abstract][Full Text] [Related]
5. Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.
Letko M; Booiman T; Kootstra N; Simon V; Ooms M
Cell Rep; 2015 Dec; 13(9):1789-99. PubMed ID: 26628364
[TBL] [Abstract][Full Text] [Related]
6. Crystal Structure of a Soluble APOBEC3G Variant Suggests ssDNA to Bind in a Channel that Extends between the Two Domains.
Maiti A; Myint W; Delviks-Frankenberry KA; Hou S; Kanai T; Balachandran V; Sierra Rodriguez C; Tripathi R; Kurt Yilmaz N; Pathak VK; Schiffer CA; Matsuo H
J Mol Biol; 2020 Nov; 432(23):6042-6060. PubMed ID: 33098858
[TBL] [Abstract][Full Text] [Related]
7. Nanoscale Characterization of Interaction of APOBEC3G with RNA.
Pan Y; Sun Z; Maiti A; Kanai T; Matsuo H; Li M; Harris RS; Shlyakhtenko LS; Lyubchenko YL
Biochemistry; 2017 Mar; 56(10):1473-1481. PubMed ID: 28029777
[TBL] [Abstract][Full Text] [Related]
8. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
9. HIV restriction factor APOBEC3G binds in multiple steps and conformations to search and deaminate single-stranded DNA.
Morse M; Naufer MN; Feng Y; Chelico L; Rouzina I; Williams MC
Elife; 2019 Dec; 8():. PubMed ID: 31850845
[TBL] [Abstract][Full Text] [Related]
10. Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G.
Kouno T; Luengas EM; Shigematsu M; Shandilya SM; Zhang J; Chen L; Hara M; Schiffer CA; Harris RS; Matsuo H
Nat Struct Mol Biol; 2015 Jun; 22(6):485-91. PubMed ID: 25984970
[TBL] [Abstract][Full Text] [Related]
11. The HDAC6/APOBEC3G complex regulates HIV-1 infectiveness by inducing Vif autophagic degradation.
Valera MS; de Armas-Rillo L; Barroso-González J; Ziglio S; Batisse J; Dubois N; Marrero-Hernández S; Borel S; García-Expósito L; Biard-Piechaczyk M; Paillart JC; Valenzuela-Fernández A
Retrovirology; 2015 Jun; 12():53. PubMed ID: 26105074
[TBL] [Abstract][Full Text] [Related]
12. Structural Determinants of the APOBEC3G N-Terminal Domain for HIV-1 RNA Association.
Fukuda H; Li S; Sardo L; Smith JL; Yamashita K; Sarca AD; Shirakawa K; Standley DM; Takaori-Kondo A; Izumi T
Front Cell Infect Microbiol; 2019; 9():129. PubMed ID: 31165049
[TBL] [Abstract][Full Text] [Related]
13. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Vif-Mediated Degradation of APOBEC3G through Competitive Binding of Core-Binding Factor Beta.
Miyagi E; Welbourn S; Sukegawa S; Fabryova H; Kao S; Strebel K
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941780
[TBL] [Abstract][Full Text] [Related]
15. Understanding the structural basis of HIV-1 restriction by the full length double-domain APOBEC3G.
Yang H; Ito F; Wolfe AD; Li S; Mohammadzadeh N; Love RP; Yan M; Zirkle B; Gaba A; Chelico L; Chen XS
Nat Commun; 2020 Jan; 11(1):632. PubMed ID: 32005813
[TBL] [Abstract][Full Text] [Related]
16. APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells.
Batisse J; Guerrero SX; Bernacchi S; Richert L; Godet J; Goldschmidt V; Mély Y; Marquet R; de Rocquigny H; Paillart JC
J Virol; 2013 Jun; 87(11):6492-506. PubMed ID: 23576497
[TBL] [Abstract][Full Text] [Related]
17. Differential Contributions of Ubiquitin-Modified APOBEC3G Lysine Residues to HIV-1 Vif-Induced Degradation.
Turner T; Shao Q; Wang W; Wang Y; Wang C; Kinlock B; Liu B
J Mol Biol; 2016 Aug; 428(17):3529-39. PubMed ID: 27297094
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for HIV-1 antagonism of host APOBEC3G via Cullin E3 ligase.
Ito F; Alvarez-Cabrera AL; Liu S; Yang H; Shiriaeva A; Zhou ZH; Chen XS
Sci Adv; 2023 Jan; 9(1):eade3168. PubMed ID: 36598981
[TBL] [Abstract][Full Text] [Related]
19. Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway.
Chen C; Ma X; Hu Q; Li X; Huang F; Zhang J; Pan T; Xia J; Liu C; Zhang H
Retrovirology; 2017 Dec; 14(1):56. PubMed ID: 29258557
[TBL] [Abstract][Full Text] [Related]
20. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
